Business News • PR NewsWire • AbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® + EXVIERA® in Chronic Hepatitis C Patients with Renal Impairment at The International Liver Congress™ 2015

AbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® + EXVIERA® in Chronic Hepatitis C Patients with Renal Impairment at The International Liver Congress™ 2015

AbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® + EXVIERA® in Chronic Hepatitis C Patients with Renal Impairment at The International Liver Congress™ 2015

VIENNA, April 25, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new, preliminary safety and efficacy data from the first cohort of its ongoing, Phase 3b RUBY-I study. RUBY-I is evaluating VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir...

View More : http://www.prnewswire.com/news-releases/abbvie-presents-late-breaking-preliminary-phase-3b-data-with-viekirax--exviera-i...

Releted News by prnewswire

Harper Government improves accessibility for Canadians with disabilities in Peterborough and nearby Ontario townships

Die Geschäftsfrau und Philanthropin Yelena Baturina wird zur Botschafterin für WE-Women for Expo und stiftet den "Pool of Thoughts" für Mailands botanischen Garten

Two World-Class Brands Deepen the Partnership as Harman Flagship Store Moves in to the TCL Tower